George Hemstreet, MD, PhD
George  . Hemstreet, MD, PhD

George . Hemstreet, MD, PhD

Professor
School of Medicine

Academic Appointments

Department

  • Urology

Position

  • Professor

Biography

Dr. Hemstreet as a clinician scientist obtained his Ph.D. following his medical training in Microbiology and Immunology. After completing his surgical residency his career developed as a clinical urologist and basic science researcher by utilizing his immunological background as it applied to tumor immunology and infectious disease and later to biophysical cytochemistry. Subsequently his career interests focused on the development of and validation of quantitative fluorescence image analysis for assaying proteins in single cells and more recently to the area of tissues proteomics (zeptomole level with a 15% variance). Early in his career he pioneered the field of molecular epidemiology and biomarkers when he scientific and medical director of Notification and Screening Program for workers exposed to aniline dyes sponsored by Workers Institute and NIOSH. This study contributed to defining the then new discipline of molecular epidemiology. The microscope based fluorescence technique used in this study was automated incorporating fluorescence imaging. This technology was later recognized by the National Research Council where Dr. Hemstreet served as Vice Committee for the committee on Biomarkers in Urinary Toxicology. The two year sojourn spawned the EDRN and served as a basis for increasing the funding for cancer prevention at the NCI. This leadership imitative was preceded by the programming of a fluorescence microscope for single cell proteomics. The sensitivity of this methodology defined alterations in nuclear and cytoplasmic actin depolymerization (G-actin/F-actin ratio) explaining the cardinal single cell signature of malignancy (nuclear cytoplasmic ratio). The instrumentation and the analysis of over 15,000 samples scientifically validated Slaughter”s hypothesis of molecular field disease in bladder cancer biopsy specimens which subsequently was further verified by a large bladder cancer six year longitudinal cohort study in five Chinese provinces. These concepts were vitally important for the integrated conceptual appreciation of biomarkers as it related to defining malignant associated dysplasia’s (Linxien Study) that heralded the malignant cancer phenotype. During these studies Dr. Hemstreet was the founder of a biomedical research company CytoDiagnostics which became the centerpiece and financial backbone for the establishment the Biomedical Research Park Associated with the University of Oklahoma Medical Center. The role of biomarkers for pharmacological monitoring of drug effects on cellular differentiation so key to chemoprevention was introduced. More recently, a method was developed for studying the proteomic changes in the human tissues microenvironment, a concept initially hypothesized in the National Research Council Report.

Publications and Presentations

Articles

  • Wang J, Wang FW, LaGrange CA, Hemstreet GP. Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate. PMID: 20141680, Rare Tumors, 2(3), e47 130-34, 2010
  • Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, Catalona WJ, Cookson MS, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP 3rd, Howe RJ, Lange PH, Lilja H, Loughlin KR, Mohler J, Moul J, Nadler RB, Patterson SG, Presti JC, Struop AM, Wake R, Wei JT. “NCCN Clinical Practice Guidelines in Oncology: Prostate cancer early detection.” J Natl Compr Caner Network, PMID: 20141680, 8(2), 240-62, 2010

Publications

  • Hemstreet GP 3rd, Rossi GR, Pisarev VM, Enke CA, Helfner L, Hauke RJ, Tennant L, Ramsey WJ, Vahanian NN, Link CJ, . Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens. J Immunother, 36(1), 57-65, 2013
  • Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP 3rd, Crawford ED, Thompson IM Jr, Klein EA. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology, 79(3), 633-637, 2012
  • Kaushik D, Teply BA, Hemstreet GP 3rd. Novel treatment strategy for refractory hemorrhagic cystitis following radiation treatment of genitourinary cancer : Use of 980-nm diode laser. Lasers Med Sci. PMID: 22370618, DOI: 10.1007/s10103-012-1070-y, 27(5), 1099-1102, 2012
  • Wang J, Wang FW, LaGrange CA, Hemstreet GP. Younger Age is an Independent Predictor for Poor Survival in Patients with Signet Ring Prostate Carcinoma. Prostate Cancer. doi:10.1155/2011/216169, vol. 2011, Article ID 216169, 8 pages, 2011
  • Park ES, Boedeker BH, Hemstreet GP. The Initiation of a Preoperative and Postoperative Telemedicine Urology Clinic. Stud Health Technol Inform, 163, 425-7, 2011
  • Villanueva, C. Hemstreet GP. The approach to the Difficult Urethral Catheterization Among Urology Residents in the United States. Int Braz J Urol, Nov-Dec;36(6), 710-5; discussion 715-7., 2010
  • Wang J, Wang FW, Hemstreet GP 3rd. Younger age is an independent predictor for poor survival in patients with signet ring prostate carcinoma. Prostate Cancer. PMCID: PMC3216005, DOI: 10.1155/2011/216169, 2011, PMID: 22110982, 2010
  • Villanueva C, Hemstreet GP 3rd. Experience with a Difficult Urethral Catheterization Algorithm at a University Hospital, Current Urology Reports, 2010
  • Huang D, Casale G, Tian J, Lele S, Pisarev V, Simpson M, Hemstreet GP. “UDP-glucose deydrogenase as a novel field-specific candidate biomarker of prostate cancer. Int J Cancer, 126(2), 315-27, 2010
  • Richardson T, McCanse W, Casale G, Huang D, Tian J, Elkahwaji J, Subodh L, Hemstreet GP. “Tissue based quantification of 8-hydroxy-2’deoxyguanosine (8-OhdG) in human prostate biopsies using quantitative fluorescence imaging analysis”, Urology, 74(5), 1174-9, 2009
  • Villanueva C, Hemstreet GP 3rd. Difficult male urethral catheterization: a review of different approaches. Int Braz J Urol, Jul-Aug;34(4), 401-11; discussion 412, 2008
  • Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP 3rd, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res, 14(1), 224-9, 2008
  • Carreón T, Kadlubar FF, Ruder AM, Schulte PA, Hayes RB, Waters M, Grant DJ, Boissy R, Bell DA, Hemstreet GP 3rd, Yin S, Lemasters GK, Rothman N. Reply to the letter to the Editor: “N-Acetyltransferases and the susceptibility to benzidine-induced bladder carcinogenesis”. Int J Cancer, 121(7), 1637-9; author reply 1640-1, 2007
  • Kawachi MH, Bahnson RR, Barry M, Carroll PR, Carter HB, Catalona WJ, Epstein JI, Etzioni RB, Hemstreet, GP 3rd,Howe RJ, Kopin JD, Lange PH, Lilja H, Mohler J, Moul J, Nadler RB, Pattersonn S, Pollack S, Pollack A, Presti JC, Stroup AM, Urban DA, Wake R, Wei JT: National comprehensive network. “Prostate cancer early detection. Clinical practice guidelines in oncology”, 5(7), 714-36, 2007
  • Huang D, Casale GP, Tian J, Wehbi N, Abrahams NA, Kaleem Z, Smith LM, Johansson SL, Elkahwaji JE, Hemstreet GP 3rd. Quantitative fluorescence imaging analysis for cancer biomarker discovery: application to β-Catenin in archived prostate specimens. 2007Jul; . Cancer Epidemiol, Biomarkers Prev, (16)7:, 1371-1381, 2007
  • Lewis TE, Milam TD, Klingler DK, Rao PS, Jaggi M, Smith DJ, Hemstreet GP and K.C. Balaji; Tissue Transglutaminase Interacts with protein kinase A anchor protein 13 in prosate cancer. Urol Oncol. 2005, Nov-Dec;, 23(6), 407-12, 2006
  • Carreon T, Ruder AM, Schulte PA, Hayes RB, Rothman N, Waters M, Grant DJ, Boissy R, Bell DA, Kadlubar FF, Hemstreet GP, Yin S, LeMasters GK. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine. Int J Cancer, 18(1), 161-8, 2006
  • Habuchi T, Marberger M, Droller MJ, Hemstreet GP, Grossman HB, Schalken JA, Schmitz-Drager BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Hautmann SH, Messing E, Fradet Y, Lokeshwar VB. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers; Urology, Urology, 66(6 Suppl 1), 64-74, 2005
  • Lokeshwar VB, Habuchi T, Grossman, HB, Murphy WM, Hautmann SH, Hemstreet GP, Bono AV, Getzenberg RH, Goebell P, Schmitz-Drager BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers, Urology, 66 (6 suppl 1), 35-63, 2005
  • Lewis TE, Milam TD, Klingler DK, Rao PS, Jaggi M, Smith DJ, Hemstreet GP and K.C. Balaji; Tissue Transglutaminase Interacts with protein kinase A anchor protein 13 in prosate cancer. Urol Oncol, 23(6), 407-12, 2005
  • Klinger DW, Hemstreet GP, Balaji KC, Feasibility of robotic radical nephrectomy – Initial results of a single institution pilot study, Urology, 65(6), 1086-9, 2005
  • Jaggi M, Rao PS, Smith DJ, Wheelock MJ, Johnson KR, Hemstreet GP, Balaji KC. E-cadherin Phosphorylation by protein kinase D1/protein kinase C (mu) is associated with altered cellular aggregation and motility in prostate cancer; Cancer Res, 65:(2), 483-492, 2005
  • Hemstreet GP, Wang W. Genotypic and phenotypic biomarker profiles for individual risk assessment and cancer detection (lessons from bladder cancer risk assessment in symptomatic patients and workers exposed to benzidine). Front Biosci, 9, 2671-9, 2004
  • Balaji KC, Yohannes P, McBride CL,Oleynikov D. Hemstreet GP. Feasibility of robot-assisted totally intracorporeal laparoscopic ileal conduit urinary diversion: initial results of a single institutional pilot study, Urology, 63(1), 51-5, 2004
  • Rao PS, Jaggi M, Smith DJ, Hemstreet GP, Balaji KC. Metallothionein 2A interacts with the kinase domain of PKCmu in prostate cancer. Biochem Biophys Res Commun, 310(3):, 1032-8, 2003
  • Jaggi M, Rao PS, Smith DJ, Hemstreet GP, Balaji KC. Protein kinase C mu is down-regulated in androgen-independent prostate cancer. Biochem Biophys Res Commun, 307(2), 254-60, 2003
  • Hurst RE, Kyker KD, Bonner RB, Bowditch RD, Hemstreet, GP. Matrix-dependent plasticity of the malignant phenotype of bladder cancer cells, Anticancer Res., 23(4), 3119-28, 2003
  • Hemstreet GP, Yin S, Ma Z, Bonner RB, Bi W, Rao JY, Zang M, Zheng Q, Bane B, Asal N, Li G, Feng P, Hurst RE, Wang W. Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine: J Natl Cancer Inst, 93(6), 427-36, 2003
  • Hemstreet GP III. Erectile dysfunction is associated with brachytherapy, conformal radiation, or radical surgery, Oncology, 17(1), 68-70, 2003
  • Wehbi,NK, Dugger AL, Bonner RB, Pitha JV, Hurst RE, Hemstreet GP. Pan-cadherin as a high level phenotypic biomarker for prostate cancer, Journal of Urology, 167(5), 2215-21, 2002
  • Rao J, Seligson D, Hemstreet GP: Protein expression analysis using quantitative fluorescence image analysis on tissue microarray slides, Biotechniques, 32(4), 924-6, 928-30, 932, 2002
  • Birckbichler, PJ, Bonner RB, Hurst RE, Bane BL, Pitha JV, and Hemstreet GP. Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma, Cancer, 89(2), 412-13, 2000
  • Hemstreet, GP, Bonner RB, Hurst RE, Bell D, Bane BL. Abnormal G-Actin content in single prostate cells as a biomarker for prostate cancer. PMID 11129989, Cancer Detection and Prevention., 24(5), 464-72, 2000

Editing and Reviews

  • Hemstreet GP. Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. (Editorial comment), Journal of Urology, 166(5), 1665, 2001

Research and Scholarship

Current Research Projects

  • Current research interest resides in defining the utility of modern mass spectroscopy for biomarker discovery and validation by quantitative fluorescence imaging relative to phosphoproteomic signaling.

Awards and Honors

  • Unemed New Invention Contributor 2009, UNMC, 2009
  • #5997519 - Fluid Collection Device, 1998
  • #5824495 - Cell Fixative & Preparation Composition Kit & Method, 1997
  • #5735834 - Fluid Collection Device, 1996
  • #5741648 - Cell Analysis Method using QFIA, 1996
  • Citation for Meritorious Services to the Oklahoma City Bombing Victims, American Medical Association, 1995
  • #5599331 - Fluid Collection Device, 1995
  • Biological Markers in Urinary Toxicology, National Research Council, ed. Washington, DC, 1995
  • Honorable Visiting Professor, Chinese Academy of Medical Sciences, Beijing, China, 1995
  • #5380289 - Fluid Collection Device, 1993
  • #5733721 - Cell Analysis Method using Quantitative Fluorescence Image Analysis (QFIA), 1992
  • #5387191 - Flushing Needle, 1991
  • George Lynn Cross Research Professorship, The University of Oklahoma, 1991
  • #5081999 - Biosample Aspirator, 1990
  • #4982739 - Biosample Aspirator, 1989
  • Visiting Professor, Chinese Academy of Preventive Medicine, 1987
  • Young Investigators Award, NIH, 1978